Winter Park, Florida — January 8, 2026 — Leads & Copy — ADIA Nutrition, Inc. (OTCQB: ADIA) has appointed Dawn Bell as Chief Revenue Officer (CRO) through its subsidiary, ADIA Labs, the company announced today.
Bell brings more than 15 years of experience as a sales strategist in the medical device and pharmaceutical industries. In her new role, Bell will strengthen revenue for ADIA Nutrition and its laboratory operations. Her primary contribution will be ensuring shared success across the entire ecosystem by partnering with doctors and clinics to increase their revenue.
She will provide guidance and strategies to integrate the company’s regenerative therapies and diagnostic services into practices specializing in regenerative medicine, orthopedics, pain management, and wellness.
This appointment coincides with Adia Med of Winter Park preparing to launch its first Institutional Review Board (IRB)-approved clinical study focused on autism.
Larry Powalisz, CEO of ADIA Nutrition, said Bell brings the experience and vision needed to advance the company’s growth. He added that her impact will be in equipping physician and clinic partners with the tools, training, and support to grow their practices and improve patient outcomes.
ADIA Nutrition continues to gain momentum with revenue growth, an expanding nationwide network of clinic partnerships, strategic initiatives, and the upcoming launch of its first IRB-approved autism clinical study at Adia Med of Winter Park.
ADIA Nutrition Inc., based in Winter Park, Florida, specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.
Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia’s regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia’s continued mission to expand access to advanced stem cell solutions.
Contact:
Larry Powalisz
ceo@adiamed.com
321-788-0850
Source: ADIA Nutrition
